Loading clinical trials...
Loading clinical trials...
A Single-arm Clinical Study on the Efficacy and Safety of the Novel Oncolytic Virus Ad-TD-nsIL12 Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma
Conditions
Interventions
Novel oncolytic virus Ad-TD-nsIL12（BioTTT001）
Locations
1
China
Sanbo Brain Hospital, Capital Medical University
Beijing, Chaoyang District, China
Start Date
March 31, 2026
Primary Completion Date
April 30, 2028
Completion Date
April 30, 2028
Last Updated
March 16, 2026
NCT06829173
NCT06624371
NCT06660056
NCT06763965
NCT04482933
NCT04552756
Lead Sponsor
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions